Literature DB >> 22901393

Biologically active ester derivatives as potent inhibitors of the soluble epoxide hydrolase.

In-Hae Kim1, Kosuke Nishi, Takeo Kasagami, Christophe Morisseau, Jun-Yan Liu, Hsing-Ju Tsai, Bruce D Hammock.   

Abstract

Substituted ureas with a carboxylic acid ester as a secondary pharmacophore are potent soluble epoxide hydrolase (sEH) inhibitors. Although the ester substituent imparts better physical properties, such compounds are quickly metabolized to the corresponding less potent acids. Toward producing biologically active ester compounds, a series of esters were prepared and evaluated for potency on the human enzyme, stability in human liver microsomes, and physical properties. Modifications around the ester function enhanced in vitro metabolic stability of the ester inhibitors up to 32-fold without a decrease in inhibition potency. Further, several compounds had improved physical properties.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22901393      PMCID: PMC3432147          DOI: 10.1016/j.bmcl.2012.07.074

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  29 in total

Review 1.  New role for epoxyeicosatrienoic acids as anti-inflammatory mediators.

Authors:  W B Campbell
Journal:  Trends Pharmacol Sci       Date:  2000-04       Impact factor: 14.819

2.  Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids.

Authors:  K Node; X L Ruan; J Dai; S X Yang; L Graham; D C Zeldin; J K Liao
Journal:  J Biol Chem       Date:  2001-02-22       Impact factor: 5.157

3.  Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.

Authors:  Z Yu; F Xu; L M Huse; C Morisseau; A J Draper; J W Newman; C Parker; L Graham; M M Engler; B D Hammock; D C Zeldin; D L Kroetz
Journal:  Circ Res       Date:  2000-11-24       Impact factor: 17.367

Review 4.  Targeting soluble epoxide hydrolase for inflammation and pain - an overview of pharmacology and the inhibitors.

Authors:  Sivaram Pillarisetti; Ish Khanna
Journal:  Inflamm Allergy Drug Targets       Date:  2012-04

Review 5.  Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase.

Authors:  J H Capdevila; J R Falck; R C Harris
Journal:  J Lipid Res       Date:  2000-02       Impact factor: 5.922

6.  Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension.

Authors:  John D Imig; Xueying Zhao; Jorge H Capdevila; Christophe Morisseau; Bruce D Hammock
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

7.  Structural refinement of inhibitors of urea-based soluble epoxide hydrolases.

Authors:  Christophe Morisseau; Marvin H Goodrow; John W Newman; Craig E Wheelock; Deanna L Dowdy; Bruce D Hammock
Journal:  Biochem Pharmacol       Date:  2002-05-01       Impact factor: 5.858

8.  Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells.

Authors:  B Yang; L Graham; S Dikalov; R P Mason; J R Falck; J K Liao; D C Zeldin
Journal:  Mol Pharmacol       Date:  2001-08       Impact factor: 4.436

9.  Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility.

Authors:  In-Hae Kim; Christophe Morisseau; Takaho Watanabe; Bruce D Hammock
Journal:  J Med Chem       Date:  2004-04-08       Impact factor: 7.446

10.  Evaluation of fish models of soluble epoxide hydrolase inhibition.

Authors:  J W Newman; D L Denton; C Morisseau; C S Koger; C E Wheelock; D E Hinton; B D Hammock
Journal:  Environ Health Perspect       Date:  2001-01       Impact factor: 9.031

View more
  7 in total

1.  Investigation of the binding mode of 1, 3, 4-oxadiazole derivatives as amide-based inhibitors for soluble epoxide hydrolase (sEH) by molecular docking and MM-GBSA.

Authors:  Leila Karami; Ali Akbar Saboury; Elham Rezaee; Sayyed Abbas Tabatabai
Journal:  Eur Biophys J       Date:  2016-12-07       Impact factor: 1.733

2.  Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.

Authors:  Sandra Codony; Elena Valverde; Rosana Leiva; José Brea; M Isabel Loza; Christophe Morisseau; Bruce D Hammock; Santiago Vázquez
Journal:  Bioorg Med Chem       Date:  2019-08-26       Impact factor: 3.641

3.  Structure-activity relationships of substituted oxyoxalamides as inhibitors of the human soluble epoxide hydrolase.

Authors:  In-Hae Kim; In-Hee Lee; Hisashi Nishiwaki; Bruce D Hammock; Kosuke Nishi
Journal:  Bioorg Med Chem       Date:  2014-01-03       Impact factor: 3.641

4.  Rational Design of Potent and Selective Inhibitors of an Epoxide Hydrolase Virulence Factor from Pseudomonas aeruginosa.

Authors:  Seiya Kitamura; Kelli L Hvorecny; Jun Niu; Bruce D Hammock; Dean R Madden; Christophe Morisseau
Journal:  J Med Chem       Date:  2016-05-04       Impact factor: 7.446

5.  Design, synthesis and biological evaluation of 4-benzamidobenzoic Acid hydrazide derivatives as novel soluble epoxide hydrolase inhibitors.

Authors:  Elham Rezaee Zavareh; Mahdi Hedayati; Laleh Hoghooghi Rad; Soraya Shahhosseini; Mehrdad Faizi; Sayyed Abbas Tabatabai
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

6.  Effect of a Soluble Epoxide Hydrolase Inhibitor, UC1728, on LPS-Induced Uveitis in the Rabbit.

Authors:  Gillian J McLellan; Zeynep Aktas; Elizabeth Hennes-Beean; Aaron W Kolb; Inna V Larsen; Emily J Schmitz; Hilary R Clausius; Jun Yang; Sung Hee Hwang; Christophe Morisseau; Bora Inceoglu; Bruce D Hammock; Curtis R Brandt
Journal:  J Ocul Biol       Date:  2016-01-12

7.  Intensification of Double Kinetic Resolution of Chiral Amines and Alcohols via Chemoselective Formation of a Carbonate-Enzyme Intermediate.

Authors:  Jan Samsonowicz-Górski; Anna Brodzka; Ryszard Ostaszewski; Dominik Koszelewski
Journal:  Molecules       Date:  2022-07-06       Impact factor: 4.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.